Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Celularity ( (CELU) ).
On March 6, 2026, Celularity entered an asset purchase and exclusive license agreement with NexGel granting exclusive rights to its commercial-stage biomaterials portfolio and certain development programs, for consideration of up to $35 million in cash, including a $15 million upfront payment and up to $20 million in sales-based milestones. The deal, announced publicly on March 10, 2026, is subject to customary closing conditions, including NexGel securing financing for the upfront payment, and is structured with standard representations, covenants, and termination rights.
Celularity will retain exclusive manufacturing rights for the licensed biomaterial products at its Florham Park facility, creating a continuing revenue and margin stream while also becoming eligible for royalties on future net sales of certain development-stage products. The transaction is part of a broader organizational realignment in which biomaterials-related personnel are expected to move to the commercial partner and Celularity will further reduce its workforce, lowering operating expenses and sharpening its focus on advancing a longevity-focused pipeline of placental-derived cell therapies.
By monetizing its commercial biomaterials infrastructure through non-dilutive capital and shifting operating responsibility to NexGel, Celularity aims to strengthen its balance sheet and concentrate resources on high-value clinical and manufacturing initiatives in longevity medicine. The company intends to expand opportunities in jurisdictions such as Florida, Texas, and Arizona that allow investigational use of cellular and biologic technologies, positioning itself to benefit from growing demand for therapies targeting cellular senescence, chronic inflammation, and tissue degeneration.
The most recent analyst rating on (CELU) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Neutral.
The score is primarily weighed down by weak financial performance—large ongoing losses, declining revenue, and negative equity with meaningful debt. Technicals also point to a sustained downtrend with weak momentum. Valuation offers limited support given negative earnings and no dividend, while recent corporate events are mixed: liquidity improved via financing, but dilution/regulatory and shareholder constraints remain.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Celularity Inc. is a Nasdaq-listed regenerative and cellular medicine company focused on longevity science, developing and manufacturing allogeneic and autologous cell therapies derived from postpartum placentas. The company leverages the placenta’s unique biology and scalable availability to target fundamental mechanisms of aging and age-related diseases across emerging longevity-focused markets.
Headquartered in Florham Park, N.J., Celularity operates a vertically integrated, FDA-compliant manufacturing facility that supports both commercial-stage placental-derived biomaterials and next-generation cellular therapeutics. Its strategy emphasizes capital-efficient commercialization, scalable manufacturing, and expansion into jurisdictions that permit investigational use of cellular and biologic technologies under applicable state frameworks.
Average Trading Volume: 49,205
Technical Sentiment Signal: Sell
Current Market Cap: $36.05M
For detailed information about CELU stock, go to TipRanks’ Stock Analysis page.